Vascular resistance in the prostate evaluated by colour Doppler ultrasonography: is benign prostatic hyperplasia a

Andreas P Berger1, Wolfgang Horninger, Jasmin Bektic

  • 1Department of Urology and Radiology, Medical University of Innsbruck, Austria. andreas.p.berger@uibk.ac.at

BJU International
|June 27, 2006
PubMed

Insights

High prostatic vascular resistance, measured by resistive index (RI) using colour Doppler ultrasonography (CDUS), is linked to benign prostatic hyperplasia (BPH). This finding supports the role of impaired blood flow in BPH development.

Area of Science:

  • Urology
  • Vascular Biology
  • Medical Imaging

Background:

  • Benign prostatic hyperplasia (BPH) is a common condition associated with aging.
  • Hypoxia, potentially caused by abnormal blood flow, may drive stromal growth in BPH.
  • Assessing prostatic vascular resistance could offer insights into BPH pathogenesis.

Purpose of the Study:

  • To evaluate prostatic vascular resistance and flow velocity in normal prostates, BPH, and prostate cancer using colour Doppler ultrasonography (CDUS).
  • To determine if resistive index (RI) can differentiate between BPH and prostate cancer.
  • To explore the relationship between vascular changes and BPH development.

Main Methods:

  • Prospective evaluation of 92 men (22 normal, 45 BPH, 25 prostate cancer) using CDUS.
  • Measurement of resistive index (RI) in peripheral, central, and transition zones of the prostate.
  • Histological confirmation for BPH and prostate cancer diagnoses.

Main Results:

  • Significantly higher mean RI in the transition zone of BPH patients (0.77) compared to normal and prostate cancer groups (0.65).
  • No significant RI differences in peripheral and central zones among the groups.
  • Increased arterial CDUS flow velocity in the transition zone of BPH patients.

Conclusions:

  • Elevated transition zone RI (>0.75) is indicative of BPH.
  • Results support the hypothesis that age-related impaired blood supply contributes to BPH.
  • RI measurement alone cannot exclude prostate cancer.
Abstract